Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$6.07 -0.29 (-4.56%)
Closing price 04:00 PM Eastern
Extended Trading
$6.07 0.00 (0.00%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$5.44
$6.52
50-Day Range
$6.10
$11.00
52-Week Range
$5.44
$29.46
Volume
394,206 shs
Average Volume
324,885 shs
Market Capitalization
$325.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Remove Ads
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt
**Breaking NEWS* This Company Starts To Rally As it Reduces $20 Million in Debt Discover why Notable Names like Cisco, Hewlett Packard and New York Life are Choosing to Do Business with this Growing Marketing Tech Company
UPB Upstream Bio, Inc.
Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 on January 1st, 2025. Since then, UPB shares have decreased by 63.1% and is now trading at $6.07.
View the best growth stocks for 2025 here
.

Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Upstream Bio's lock-up period expires on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Today
4/08/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$75.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+830.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.37 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$325.60 million
Optionable
N/A
Beta
N/A
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 4/8/2025 by MarketBeat.com Staff
From Our Partners